Research Site

Renton, Washington 98057

7 studies enrolling now · 36 studies all time

What they study most

COVID-19, Carcinoma, Carcinoma, Non-Small Cell Lung, Cardiovascular Disease, Chronic Obstructive Pulmonary Disorder, Cost Sharing, Acute Coronary Syndrome, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, ER-Positive HER2-Negative Breast Cancer, Epilepsy, Focal Seizures, Partial Seizures, Heart Failure

Studies at this site

• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin — Recruiting now
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus — Recruiting now
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer — Recruiting now
• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin — Recruiting now
• A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus — Recruiting now
• A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies — Recruiting now
• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event — Recruiting now
• A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone — Completed
• Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations — Running, not enrolling
• A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease — Running, not enrolling
• Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma — Completed
• Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels — Completed
• Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 — Completed
• Open Label Study of Long Term Evaluation Against LDL-C Trial — Completed
• Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study — Completed
• Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy — Completed
• Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. — Completed
• A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis — Completed
• Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study — Completed
• A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos) — Completed
• Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia — Completed
• Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin — Completed
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab — Completed
• Multiple Ascending Dose Study in Subjects With Type 2 Diabetes — Stopped early
• Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus — Completed
• An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus — Completed
• A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients — Completed
• Effect on Weight Loss of Exenatide Versus Placebo — Completed
• An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus — Completed
• Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin — Completed
• Iressa Expanded Access Program (EAP) — Completed
• GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes — Stopped early
• A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR) — Completed
• GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin — Stopped early
• G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study) — Stopped early
• GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes — Completed